Related references
Note: Only part of the references are listed.Tumor-Suppressive Effect of Adenovirus-Mediated Inhibitor of Growth 4 Gene Transfer in Breast Carcinoma Cells In Vitro and In Vivo
Zhengyi Li et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2010)
Adenovirus-Mediated ING4 Expression Suppresses Pancreatic Carcinoma Cell Growth via Induction of Cell-Cycle Alteration, Apoptosis, and Inhibition of Tumor Angiogenesis
Yu Feng Xie et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
Reviewing the current classification of inhibitor of growth family proteins
Motoko Unoki et al.
CANCER SCIENCE (2009)
The interplay between viruses and innate immune signaling: Recent insights and therapeutic opportunities
Leonie Unterholzner et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Adenovirus-mediated ING4 expression suppresses lung carcinoma cell growth via induction of cell cycle alteration and apoptosis and inhibition of tumor invasion and angiogenesis
Yufeng Xie et al.
CANCER LETTERS (2008)
Role of ING4 in human melanoma cell migration, invasion and patient survival
Jun Li et al.
CARCINOGENESIS (2008)
A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein
J. Conner et al.
GENE THERAPY (2008)
Potential for efficacy of the oncolytic herpes simplex virus 1716 in patients with oral squamous cell carcinoma
Alastair T. M. Mace et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2008)
The ING4 Tumor Suppressor Attenuates NF-κB Activity at the Promoters of Target Genes
Susan Nozell et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61
Kazuhiko Kurozumi et al.
MOLECULAR THERAPY (2008)
Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses
Akihiro Otsuki et al.
MOLECULAR THERAPY (2008)
Temporal association of the herpes simplex virus genome with histone proteins during a lytic infection
Jaewook Oh et al.
JOURNAL OF VIROLOGY (2008)
After a decade of study-ING, a PHD for a versatile family of proteins
Mohamed A. Soliman et al.
TRENDS IN BIOCHEMICAL SCIENCES (2007)
Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin α1
Jiang-Cheng Shen et al.
CANCER RESEARCH (2007)
Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy
Ta-Chiang Liu et al.
MOLECULAR THERAPY (2006)
Manipulation of the nuclear factor-κB pathway and the innate immune response by viruses
J. Hiscott et al.
ONCOGENE (2006)
Trimethylation of histone H3 lysine 4 by Set1 in the lytic infection of human herpes simplex virus 1
Jing Huang et al.
JOURNAL OF VIROLOGY (2006)
Grow-ING, Age-ING and Die-ING: ING proteins link cancer, senescence and apoptosis
M Russell et al.
EXPERIMENTAL CELL RESEARCH (2006)
ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation
Y Doyon et al.
MOLECULAR CELL (2006)
Herpes simplex virus 2 modulates apoptosis and stimulates NF-κB nuclear translocation during infection in human epithelial HEp-2 cells
JC Yedowitz et al.
VIROLOGY (2005)
Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas
M Gunduz et al.
GENE (2005)
ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation
R Pedeux et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Herpes simplex virus type 1 strain HSV1716 grown in baby hamster kidney cells has altered tropism for nonpermissive Chinese hamster ovary cells compared to HSV1716 grown in Vero cells
J Conner et al.
JOURNAL OF VIROLOGY (2005)
The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF)
A Ozer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis
I Garkavtsev et al.
NATURE (2004)
Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin
JT Mullen et al.
CANCER (2004)
ING4 induces G2/M cell cycle arrest and enhances the chemosensitivity to DNA-damage agents in HepG2 cells
X Zhang et al.
FEBS LETTERS (2004)
Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12
RJ Wong et al.
CLINICAL CANCER RESEARCH (2004)
Efficient replication by herpes simplex virus type 1 involves activation of the IκB kinase-IκB-p65 pathway
D Gregory et al.
JOURNAL OF VIROLOGY (2004)
A screen for genes that suppress loss of contact inhibition:: Identification of ING4 as a candidate tumor suppressor gene in human cancer
S Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival
S Harrow et al.
GENE THERAPY (2004)
The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor
O Gozani et al.
CELL (2003)
The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study
V Papanastassiou et al.
GENE THERAPY (2002)
被撤回的出版物: Herpes simplex virus type 1 blocks the apoptotic host cell defense mechanisms that target Bcl-2 and manipulates activation of p38 mitogen-activated protein kinase to improve viral replication (Retracted article. See vol. 96, 2022)
G Zachos et al.
JOURNAL OF VIROLOGY (2001)
Intralesional injection of herpes simplex virus 1716 in metastatic melanoma
RM MacKie et al.
LANCET (2001)
Quantitation of HSV mass distribution in a rodent brain tumor model
D Schellingerhout et al.
GENE THERAPY (2000)
Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
R Rampling et al.
GENE THERAPY (2000)
Share Paper
